Drug Profile
Research programme: long-acting insulin formulations - Arecor
Alternative Names: Highly concentrated rapid acting insulin - Arecor; Insulin glargine - Arecor; Ultra-long acting insulin glargine - ArecorLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Arecor
- Class Insulins
- Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Diabetes-mellitus in United Kingdom (Parenteral, Liquid)
- 24 Jan 2022 Long-acting insulin is still in preclinical phase for Diabetes mellitus in the UK
- 20 Jan 2022 European Patent Office grants patent with claims protecting novel compositions of insulin glargine with improved thermostability